We investigate the radiobiology of particle therapy, how this differs from radiation with conventional radiotherapy, and how different modalities of particle therapy effect the radiation response. To do this we use a range of biological models from cell culture to animal systems.
We conduct clinical epidemiological studies of late effects of cancer treatment in survivors of childhood and their offspring in national, Nordic and international settings, including molecular studies based on clinical data and biological specimens for genetic evaluations.
A main research area is motion management in both photon radiotherapy and proton therapy: How can tumor and organ motion during treatment delivery be monitored, how does it affect treatments, and how can its impact be mitigated. Other areas include radiobiology with a focus on proton FLASH therapy.
We investigate use of computational methods in radiation oncology – artificial intelligence, big data, and high-performance computer simulations. We are particularly interested in image segmentation, for various of imaging modalities, and robust treatment planning for photon and proton radiotherapy.
Our research focuses on cancer epidemiology. We incorporate molecular and genetic techniques in population-based research, and pharmacoepidemiologic studies to investigate cancer risk and prognosis. Most of our research is on breast cancer – encompassing etiology, treatment, prognosis, and survivorship.
Therapeutic drug monitoring (TDM) is the tool to improve patient outcomes and reduce healthcare costs. We investigate the role and need for monitorering of novel and classic TDM medicine (e.g. TKI) with chromatography based methods (LC-MSMS). TDM can bring personalized medicine into practice.
We investigate the correlation between advanced MRI sequences changes and cognitive decline following Proton and Photon therapy for brain cancer patients. We investigate advanced MRI technique to help improve definition of malignant regions through a priori knowledge of cell migration patterns.
Head and neck cancer is a life threatening disease and treatment often leads to severe side effects. At the Danish Center for Particle Therapy, we wish to explore this new modality; patient selection, treatment delivery, treatment of side effects, the lasting side effects as well as tumour control.
The main goal in our lab is to unravel biological chracteristics in hematological malignancies aiming at (i) improved diagnostic precision, (ii) determine patient prognosis more accurately, and (iii) to provide new markers for targeted therapy with the ultimate aim of improving patient survival.
Our lab utilizes cancer NGS data and computational tools to understand cancer evolution and to describe the temporal order of mutations. With blood-based biomarkers like ctDNA, we can track cancer evolution in vivo during and after treatment to ultimately build tools that may improve patient outcome.
My group uses statistical and computational approaches to study questions in human genomics. One focus is mutation processes in somatic and germline cells, including the rate, pattern, and effects of new mutations. Another focus is the development of machine learning methods for precision medicine.
Our research group study benefits and harms of breast, colorectal and cervical cancer screening. Our aim is to bring forward precise estimates of the benefits and harms of cancer screening and to improve cancer screening programmes through studies on how to individualize cancer screening and improve follow-up after cancer screening.
My translational research is anchored in a multidisciplinary teamwork and developed in a patient-centered, clinical setting. We focus on 1) indications for radiotherapy in breast and head/neck cancer and 2) phenotypical appearances of precursor lesions in the breast (incl. DCIS and apocrine lesions).